(24/7 MARKET NEWS) – Neoleukin Therapeutics, Inc., (NASDAQ: NLTX) disclosed, after yesterday’s market close, that it engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value, including a sale, merger, divestiture of assets, licensing or other strategic transaction.
Neoleukin Therapeutics is trading at $0.69, up $0.16 (+30.67%), on 2.2 million premarket shares.
Its 52-week trading range is $0.375 to $2.52. It’s trading at 2023 highs and its next key inflection point is $0.72. If it can break through the 72-cent inflection point, it’s set up for a potential run to $1+.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
